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Introduction
Chronic myeloid leukemia (CML) is characterized by the presence 
of the BCR-ABL translocation,1 and is known to be particularly 
immunosensitive. The high susceptibility of CML to immune 
destruction has been evidenced by the relatively high rates of 
durable remission achieved following hematopoietic stem cell 
transplantation (HSCT) and donor lymphocyte infusion (DLI).2 
However, the utility of these treatments is often undermined by 
the risks of severe toxicity, most commonly in the form of acute 
or chronic graft-versus-host disease (GVHD). To overcome these 
limitations, therapeutic cancer vaccines for CML have been devel-
oped for the specific activation of the immune system against 
CML cells.3-7 Whole tumor cell-based vaccination has emerged as a 
promising strategy to treat a variety of malignancies,8-12 and has the 
advantage—over peptide-based approaches—of providing a range 
of antigens for the stimulation of polyclonal immune responses. 
In particular, the BCR-ABL+ K562 cell line has been shown to be 
amenable to large-scale manufacture, and has been developed as a 
clinical grade vaccine reagent.13,14
To determine the efficacy of cancer vaccines, methods are 
needed to monitor the development of antitumor immunity. 
BcR-aBL+ K562 cells hold clinical promise as a component of cancer vaccines, either as bystander cells genetically 
modified to express immunostimulatory molecules, or as a source of leukemia antigens. To develop a method for 
detecting T-cell reactivity against K562 cell-derived antigens in patients, we exploited the dendritic cell (Dc)-mediated 
cross-presentation of proteins generated from apoptotic cells. We used UVB irradiation to consistently induce apoptosis 
of K562 cells, which were then fed to autologous Dcs. These Dcs were used to both stimulate and detect antigen-specific 
cD8+ T-cell reactivity. as proof-of-concept, we used cross-presented apoptotic influenza matrix protein-expressing K562 
cells to elicit reactivity from matrix protein-reactive T cells. Likewise, we used this assay to detect increased anti-cML 
antigen T-cell reactivity in cML patients that attained long-lasting clinical remissions following immunotherapy (donor 
lymphocyte infusion), as well as in 2 of 3 cML patients vaccinated with lethally irradiated K562 cells that were modified 
to secrete high levels of granulocyte macrophage colony-stimulating factor (GM-csF). This methodology can be readily 
adapted to examine the effects of other whole tumor cell-based vaccines, a scenario in which the precise tumor antigens 
that stimulate immune responses are unknown.
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This can readily be accomplished with peptide-based vaccines, 
as the immunizing epitopes are known. In contrast, whole tumor 
cell-based vaccines by definition comprise a complex mixture 
of antigens, and those specically targeted by therapy-induced 
immunity are unknown. An attractive approach to this challenge 
is to employ whole tumor cells themselves as as an antigen source, 
enabling the screening of all tumor antigens to which a patient 
was exposed. On the other hand, whole tumor cells in their natu-
ral state are often poorly immunogenic, and may only weakly 
stimulate an immune response.
One strategy for displaying antigens derived from whole 
tumor cells is through their cross-presentation by antigen pre-
senting cells (APCs), such as dendritic cells (DCs). Apoptotic 
bodies can be efficiently ingested, processed and their anti-
gens cross-presented on MHC Class I molecules by immature 
dendritic cells (iDCs), leading to T-cell activation.15,16 This 
cross-strategy has previously been developed for DC-based vac-
cines.17-19 Here, we describe the optimization and application of 
a K562 cell-based assay to detect CML-associated immunity fol-
lowing the administration of an effective immunotherapy for 
CML, DLI, as well as following K562 cell-based vaccination. 
Our studies demonstrate that developing a whole cell-based 1096  OncoImmunology  Volume 1 Issue 7
65–75% total apoptosis (AnnexinV+PI+) at 15 h 
post exposure (Fig. 2B). We thus selected these 
energies and time points for inducing apoptosis of 
K562 cells in subsequent experiments.
To ensure that iDCs are capable of taking up 
apoptotic K562 cells, iDCs from normal donors 
were stained with the green fluorescent dye 
PKH2. These labeled iDCs were then co-cultured 
with K562 cells that had been labeled with a red 
fluorescent dye (PKH26) for 24 h at ratios of 1:1, 
1:2, 1:5 and 1:9. A higher ratio of K562 cells to 
iDCs generally resulted in higher rates of phago-
cytosis. High levels of phagocytosis of approxi-
mately 80–85% (visualized as double positive cells 
on flow cytometry) were observed at physiological 
temperature (Fig. 3). On the other hand, minimal 
phagocytosis was observed when the same process 
was performed at 4°C.
Cross-presenting DCs effectively stimu-
late antigen-specific T cells. We next examined 
whether apoptotic K562 cells can be effectively processed and 
cross-presented by DCs to stimulate antigen-specific T cells. For 
these experiments, we used the well-characterized HLA-A*0201 
restricted and immunodominant influenza M1 epitope as a 
model antigen.18,23,24 We introduced the influenza matrix pro-
tein into K562 cells through DNA plasmid nucleofection. We 
reasoned that if we could induce expression of this protein (and 
consequently of the M1 epitope), detection of M1-specific CD8+ 
T-cell immunity from normal HLA-A2+ volunteers by ELISpot 
assay would confirm that cross-presentation of K562 antigens 
had taken place.
As shown in Figure 4A (inset), we could achieve expression of 
influenza matrix protein in K562 cells (M1-K562) by nucleofec-
tion. We then induced early apoptosis of M1-expressing K562 
cells using the conditions described above. These apoptotic cells 
were fed to HLA-A2+ DCs isolated from normal adult volunteers, 
which were then used to stimulate autologous CD8+ T cells. As 
expected, we found that DCs fed with apoptotic M1-K562 cells 
could induce M1-specific CD8+ T-cell responses (average 5.25 
spots/100,000 CD8+ T cells; p = 0.04) (Fig. 4A). In contrast, 
apoptotic K562 cells or non-cross-presented M1-K562 cells alone 
(average 1.5 spots and 0.5 spots/100,000 cells, respectively), or 
DCs fed with apoptotic K562 cells lacking expression of the 
influenza matrix protein (0.75 spots/100,000 cells) generated 
only minimal reactivity. These results demonstrate that the cross-
presentation of antigens by DCs can effectively be used to detect 
T-cell reactivity.
CML-specific reactivity can be detected following anti-CML 
immunotherapy. DLI is a highly effective immunotherapy for 
the treatment of transplanted patients with relapsed CML. In 
this procedure, donor lymphocytes are infused into patients, typi-
cally in the absence of further chemo- or radio-therapy, leading to 
durable remission in 75–80% patients.25 Numerous reports have 
described the generation of CML antigen-specific antibodies and 
CD8+ T-cell responses following DLI.26-28 We therefore examined 
this group of patients for evidence of increased anti-K562 T-cell 
disease-specific assay that can be readily applied to the monitor-
ing of cell-based cancer vaccines is feasible.
Results
Immature DCs effectively phagocytose apoptotic K562 cells. 
Several studies have identified that apoptosis results in efficient 
antigen cross-presentation to T cells.15,16,18 We sought to adapt 
this concept for developing an assay to monitor the immunologic 
activity of K562 cell-based tumor vaccines. As schematically rep-
resented in Figure 1, our workflow was to first optimize con-
ditions for K562 cell death and for phagocytosis by DCs. We 
then wanted to ensure that cellular antigens derived from apop-
totic K562 cells could be cross-presented to stimulate antigen-
specific T-cell responses. To this aim, we tested our assay first 
for the detection of anti-viral responses against a known immu-
nogenic viral antigen introduced into K562 cells, and second, 
for the detection of CML-specific immunity in CML patients 
successfully treated with DLI. Finally, we applied our assay to 
peripheral blood mononuclear cells (PBMCs) collected from 
CML patients who had been vaccinated with an experimental 
anti-CML immunotherapy, namely lethally irradiated K562 cells 
modified to secrete granulocyte macrophage colony-stimulating 
factor (GM-CSF) adjuvant.
Early apoptosis, defined as the stage at which cells are 
AnnexinV+ (have exposed phosphatidylserine on the cell surface) 
and PI- (have intact plasma membranes), has been identified as 
an optimal stage the uptake of apoptotic cells by DCs.20,21 We 
selected UVB as the method of apoptosis, as this is an estab-
lished, inexpensive and simple approach.17,18,21,22 We investigated 
a range of intensities (50–2,000 mJ) and followed cells over a 
period of 2 to 48 h (Fig. 2A). Intensities ranging from 300 to 
500 mJ consistently produced a high rate of early K562 apop-
tosis, which was not seen at lower intensities. Intensities higher 
than 500 mJ caused rapid necrosis. Irradiation with 400 mJ con-
sistently resulted in approximately 35–45% early apoptosis, and 
Figure 1. schema for developing a cross-presentation assay for measuring immunoreac-
tivity to K562 cells.reactivity from 101 spots/100,000 cells prior to vaccination, to 
154.5 spots/100,000 cells following the 5th vaccine, that then 
immunity developing upon DLI. We selected PBMC 
samples from 4 DLI-responsive patients (Patients 
DLI1–4), collected before and after DLI (at the time of 
clinical response) (Table 1). This patient group was clin-
ically homogeneous: all patients relapsed 6–15 months 
following myeloablative allogeneic HSCT, received 
CD8-depleted donor lymphocytes for the treatment of 
relapsed stable-phase CML, and promptly developed 
cytogenetic and molecular responses (median 2.75 and 
8 months post-DLI, respectively).
As shown in Figure 4B, we observed increased 
CD8+ T-cell reactivity to cross-presented apoptotic 
K562 cells in a DLI-responsive patient via ELIspot 
assays (average 16.5 spots/100,000 cells), compared 
with samples from the same patient prior to DLI (aver-
age 0 spots/100,000 cells), (p = 0.08). Furthermore, 
we detected only minimal reactivity in three CML 
patients who had been treated with non-immunologic 
therapy (imatinib, 800 mg daily for 1–7 y; Table 2). 
Our results are consistent with the detection of CML-
specific T cells following successful immunotherapy 
for CML, and suggest the potential utility of this assay 
for detecting CML specific T-cell responses following 
other forms of immunotherapy for CML.
GM-K562 vaccination elicits a T-cell response 
against CML antigens. At Dana-Farber Cancer 
Institute (DFCI), we launched a clinical trial to test 
the effects of whole tumor cell-based vaccines in 
patients with evidence of persistent minimal residual 
disease following treatment with imatinib. The vaccine 
consisted of lethally irradiated K562 cells (as a source 
of CML antigen) genetically modified to express GM-CSF 
(as adjuvant), and was administered as a series of 9 subcuta-
neous/intradermal injections. These vaccines were well-toler-
ated, although transient skin reactions at the site of injection 
were common (Fig. 5). To identify possible responses to all 
commonly expressed CML antigens, we screened patients for 
CD8+ T-cell immune responses against K562 cells.
We analyzed PBMC samples collected from three patients 
(Patients A–C) who were vaccinated with the GM-CSF 
expressing K562 vaccine (Table 3). We focused our analysis 
of CD8+ T-cell reactivity to apoptotic/cross-presented K562 
cells at three time points: approximately 30 days prior to vac-
cination; at the middle of the vaccination cycle (vaccine #5, 
or day 50); and 30 days after the final vaccine (~day 170). 
We tested CD8+ T cells against autologous DCs that were 
fed apoptotic K562 cells on ELISpot assays, compared with 
apoptotic K562 cells or autologous DCs alone. Results of the 
ELIspot assays were integrated with counts of absolute white 
blood cell (WBC) numbers, molecular detection of tumor 
burden, and immunophenotype of peripheral blood T cells 
throughout the vaccination period (Fig. 6).
For both Patients A and B, transiently increased anti-
CML T-cell reactivity was detected at mid-vaccination cycle, 
while Patient C demonstrated an absence of reactivity at all 
time points. Patient A exhibited increased anti-K562 antigen 
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Figure 2. high stable rates of apoptosis of K562 cells occur upon UVB irradiation 
(400 mJ). (A) K562 cells were cultured for 15 h after irradiation with UVB and then 
stained with annexinV and pI. early apoptotic cells were defined as annexinV+ 
and pI-, and late apoptotic cells were described as double positive. Dot plots are 
representative of a minimum of 5 experiments. (B) average results of annexinV and 
pI staining of K562 cells over 24 h following UVB irradiation at 0–500 mJ. all results 
shown are based on the average of a minimum of three experiments.
Figure 3. Dcs effectively phagocytose apoptotic K562 cells. Immature Dcs 
labeled in green (with pKh2) and apoptotic K562 cells labeled in red (with 
pKh26) were co-cultured at either 4°c (top) or 37°c (bottom) for 24 h at a 1:9 
ratio. shown are Facs results for the total population (A), and cells gated on 
the Dc population (B). Dot plots are representative of 3 experiments.1098  OncoImmunology  Volume 1 Issue 7
promising.8,29 Whole cell-based vaccines can be autologous or 
allogeneic, and may be modified (e.g., to express immunomodu-
latory molecules),30-33 fused with DCs,34-36 or unmodified (e.g., 
in the form of lysates or irradiated whole cells).37,38 The promise 
of this vaccine formulation has been primarily attributed to the 
multi-epitope nature of the immunogen. However, this same fea-
ture also creates challenges for monitoring, since the stimulating 
antigen(s) are unknown. One commonly employed monitoring 
approach uses candidate tumor-associated antigens as represen-
tative targets for immune responses. For example, in the case of 
CML, BCR-ABL, proteinase 3 and Wilms tumor 1 (WT1) all 
are highly expressed and the latter two are known to be immuno-
genic.39-42 However, these individual antigens may not be consis-
tently immunogenic across patients, and only a subset of patients 
may bear the restricting HLA-allele associated with known anti-
gen-derived epitopes. This was suggested by Smith et al.13 since 
they observed decrement in tumor burden following vaccination 
of CML patients with irradiated, modified K562 cells and devel-
opment of humoral immunity against whole tumor-cell lysates, 
but absence of detectable T-cell immunity against a panel of 
declined to 82.5 spots/100,000 cells at day 170. Likewise, T cells 
in Patient B revealed increased reactivity from 12.5 spots/100,000 
cells prior to vaccination to 25 spots/100,000 cells following the 
5th vaccine, which then declined to 13.5 spots/100,000 cells at 
day 170. None of the patients demonstrated alterations in their 
circulating WBCs. For Patients A and B, however, concomitant 
decrements of approximately one log were observed in molecular 
tumor burden (%BCR-ABL/GUS transcript). At the same time, 
an increased ratio of effector CD8+ to regulatory T cells (Tregs) 
was observed in Patient B. As for Patient C, the absence of T-cell 
reactivity was associated with a gradual one log increase in molec-
ular tumor burden over the 170 days. Of note, both Patients A and 
B subsequently demonstrated prolonged stable disease on drug 
therapy despite persistent minimal residual disease, while Patient 
C, with rising tumor burden, subsequently underwent HSCT.
Discussion
Among multiple approaches for the design of anticancer vac-
cines, whole cell-based strategies have so far proved to be the most 
Figure 4. apoptotic K562 cells when presented on Dcs can stimulate antigen-specific immunity against either introduced or native antigen. (A) K562 
cells were transfected to express M1 (see inset) and then irradiated with 400 mJ UVB to induce apoptosis. Following irradiation, these cells were co-
cultured with iDcs for 24 h and matured using a cytokine cocktail for 24 h. On eLIspot, we used cD8+ T cells alone as a negative control, M1-pulsed Dcs 
and pha as positive controls, and apoptotic M1-K562 and Dcs alone on cD8+ T-cells to establish background reactivity. There was a significant increase 
in reactivity of apoptotic M1-K562 when cross-presented by Dcs compared with apoptotic M1-K562 cells alone (*p = 0.04) or Dc cross-presented 
apoptotic K562 cells (p = 0.04). significance was determined using the two-tailed student’s t-test. all experiments were performed in duplicate wells, 
and mean spot-forming cells per 100,000 cD8+ T cells are reported. error bars represent two standard deviations. The eLIspot image is representa-
tive of more than 3 experiments, while the bar graph displays average results from four experiments, with standard deviation as shown. (B) T cells 
from pre- and post-DLI patients were tested on eLIspot against cML antigens in the form of apoptotic K562 cross-presented on Dcs, and results were 
reported as spots per 100,000 cD8+ T cells (minus background, defined as reactivity of apoptotic K562 cells alone or autologous Dcs alone on cD8+ T 
cells); p = 0.08 (student’s t test). Three patients treated with imatinib were tested as comparison, and showed no reactivity. Results are shown as means 
with error bars representing two standard deviations.www.landesbioscience.com OncoImmunology  1099
In summary, our studies using a K562 cross-presentation assay 
are suggestive of the development of anti-CML T-cell reactivity 
following whole leukemia-cell vaccination. Moreover, our results 
suggest that alternative adjuvants and/or administration sched-
ules might be required to generate more consistent responses. The 
availability of our K562 cross-presentation assay renders bench-
mark antitumor immunity measurements possible, from which 
the effects of further modifications to this promising immunogen 
formulation can be assessed.
Materials and Methods
Patient samples. Heparinized peripheral blood from normal 
volunteers and from CML patients were collected during their 
course of treatment while participating on clinical research 
protocols at the Dana-Farber Cancer Institute (DFCI), Boston 
MA. All clinical protocols were approved by the DFCI Human 
Subjects Protection Committee. The K562-GM-CSF trial also 
received approval from the Food and Drug Administration and 
the NIH Recombinant Advisory Committee on Gene Transfer. 
Peripheral blood mononuclear cells (PBMCs) from normal 
donors and patients were isolated by Ficoll/Hypaque density-
gradient centrifugation (GE Healthcare Bio-Sciences AB), cryo-
preserved with 10% DMSO, and stored in vapor-phase liquid 
nitrogen until the time of analysis.
Induction of apoptotic death of K562 cells. The BCR-ABL+ 
erythroleukemia cell line K562 (ATCC) was cultured in 162 cm2 
tissue culture flasks (Corning Inc.) from an initial concentra-
tion of 1 × 106 cells/mL, using media consisting of RPMI 1640 
(Cellgro Mediatech Inc.) with 10% fetal bovine serum (FBS) 
(Lonza). K562 cells were harvested on day 3 of culture, washed 
and suspended in PBS (Mediatech Inc.) at a concentration of 
5 × 106 cells/mL. 5 × 106 of these cells were plated in PBS in each 
well of 6-well plates (Corning Inc.,) and irradiated with UVB 
(0 to 2,000 mJ; Stratalinker UV Crosslinker 1800, Stratagene). 
known CML associated antigens.43 Presumably, T-cell reactivity 
developed against unknown CML antigens.
Our study demonstrates that developing a robust assay to 
measure T-cell reactivity to leukemia antigens from whole tumor 
cells is feasible. While other sources of whole-cell tumor antigens 
for this purpose are available, such as total RNA or tumor lysates, 
we favored using apoptotic bodies since they have been demon-
strated to efficiently provoke T-cell responses.20,22,44 We focused 
on developing a K562 cell-based assay, since clinical studies at 
our center and elsewhere have used irradiated K562 cells as a vac-
cine reagent.45,46 These studies include approaches using K562 
cells either directly as a therapeutic vaccine for myeloid leukemia 
or as bystander cells, for cell-based delivery of cytokine adjuvants 
or other immunologically active molecules.47-51 Thus, the devel-
opment of a whole cell-based assay to detect anti-K562 T-cell 
responses might enable the screening of T-cell responses to leuke-
mia antigens, for determining the immunogenicity of bystander 
cells. Finally, by detecting anti-leukemia T-cell reactivity, our 
assay can provide a stepping-stone for the discovery of novel leu-
kemia antigens, if used in combination with approaches such as 
T cell based cDNA expression library cloning.
We applied our assay to monitor three CML patients who were 
exposed to a series of 9 vaccinations with GM-CSF-secreting 
K562 cells over 20 weeks, and integrated these results with infor-
mation on molecular tumor burden and T-cell immunopheno-
type. Despite the limitations of a small sample size, the results of 
our monitoring studies stimulate further investigation. In two of 
three patients, we observed a 50% increase in T-cell reactivity to 
CML antigens during the course of vaccination. This mid-cycle 
reactivity coincided with 1-log decreases in molecular tumor bur-
den. Patient B further demonstrated a dramatic decrease in ratio 
of Tregs to effector T cells at this time. While the results for each 
assay measurement were modest, taken together they suggest that 
the vaccine has a biologic activity against CML.
Both Patients A and B were further observed to lose anti-K562 
reactivity later in the vaccine course. On the one hand, this pat-
tern could reflect the effects of the vaccine administration sched-
ule. All vaccines were initially administered weekly (×3) and then 
gradually tapered off to bi-monthly (×3), then finally as monthly 
vaccines (×3). Possibly, a high frequency of vaccination is vital to 
inducing antitumor responses, and for overcoming endogenous 
tumor-associated immunosuppression.52 Alternatively, induction 
of immunity could also activate counter regulatory mechanisms 
that function to suppress excessive immune activity, i.e., genera-
tion of exhausted and inefficient T cells with continuous anti-
genic stimulation.53 Furthermore, GM-CSF itself can function as 
both an immunostimulatory and immunosuppressive molecule.54
Table 1. clinical characteristics of DLI-treated cML patients samples whose pBMc were tested by eLIspot against the K562 cross-presentation assay
Patient Age/Sex
Months from HSCT to 
relapse
Months from HSCT 
to DLI
Months from DLI to cytogenetic 
remission
Months from DLI to molecular 
remission
DLI1 40/F 6 24 3 7
DLI2 50/M 14 25 3 8
DLI3 59/F 15 14 2.5 8
DLI4 25/F 11 54 2 12
Table 2. clinical characteristics of Imatinib treated cML patient samples 
whose pBMc were tested by eLIspot against the K562  
cross-presentation assay
Patient Age/Sex Previous therapy
Imatinib maximum 
dose; length of 
treatment
IM1 65/M
hydroxyurea, interferon, 
busulfan
800 mg/daily; 3 y
IM2 67/M hydroxyurea, interferon 800 mg/daily; 7 y
IM3 64/M hydroxyurea, interferon 800 mg/daily; 1 y1100  OncoImmunology  Volume 1 Issue 7
(50 ng/mL), IL-4 (20 ng/mL), tumor necrosis factorα (TNFα; 10 
ng/mL) and prostaglandin E-2 (PGE-2; 1 μM) (all from R&D 
Systems). We confirmed that DCs were consistently immature at 
day 6 and mature at day 8 using flow cytometric analysis with the 
markers CD80, CD86, HLA-DR and CD83.
Uptake of apoptotic bodies by antigen-presenting dendritic 
cells. For most experiments, apoptotic K562 cells served as source 
of antigenic ‘food’ for dendritic cells. Day 6 iDCs were co-cul-
tured together with irradiated K562 cells at a 1:9 ratio at 37°C in 
DC media. After 24 h, fresh DC media containing the DC mat-
uration cytokine cocktail was added to the co-culture, and incu-
bated for a further 24 h. For some experiments, we introduced 
the influenza matrix protein into K562 cells by DNA nucleofec-
tion (Nucleofector II, Amaxa Biosystems) of a plasmid encoding 
the influenza matrix protein (gift of Matthew Albert, Rockefeller 
University, NY) on day 2 of culture to create M1-expressing 
K562 cells (M1-K562). M1-K562 cells were cultured overnight 
before apoptosis induction by UVB irradiation on day 3.
To confirm phagocytosis of apoptotic K562 cells, we stained 
K562 cells red with PKH26 (Sigma-Aldrich), according to the 
manufacturer’s instructions, prior to induction of apoptosis. 
iDCs were stained green with PKH2 (Sigma-Aldrich), according 
to the manufacturer’s instructions, following harvest on day 6 
and immediately prior to co-culture of the two cell populations. 
The two stained cell populations were combined immediately 
following K562 irradiation in a 1:9 ratio and co-cultured in DC 
media for 24 h at 37°C (to encourage phagocytosis) or 4°C (to 
inhibit phagocytosis). Phagocytosis of apoptotic bodies by DCs 
was defined by the percentage of cells that were double positive 
for both PHK2 and PKH26 stains on flow cytometry.
In vitro expansion of antigen-specific T cells. To expand autol-
ogous K562 reactive T cells, we thawed autologous PBMCs and 
stimulated them for 7 days by co-culture with mature DCs that 
had been fed apoptotic K562 cells in T-cell media in 24-well plates 
(Becton Dickinson). 2–3 × 106 PBMCs were placed in each well 
and maintained in Iscove’s modified Dulbecco’s media (IMDM) 
(Cellgro Mediatech Inc.) that was supplemented with 20% FBS, 
1% glutamine (2 mM), penicillin (50 IU/mL; Mediatech Inc.) 
and streptomycin (50 μg/mL; Mediatech Inc.). IL-7 (10 ng/mL) 
was added on day 0 and 4; IL-2 (50 U/mL) (both R&D Systems) 
was also added on day 4. For some experiments, T cells were 
expanded against peptide-pulsed controls. DCs were generated as 
described and pulsed with M1 peptide (10 μg/mL) for 2 h prior to 
co-culture with autologous PBMCs for 7 d.
Detection of antigen specific T-cell responses. We used the 
ELISpot assay to measure the frequency of reactive IFNγ secret-
ing CD8+ T cells at 7 d after initiation of in vitro stimulation. 
Nitrocellulose membrane 96-well plates (Multiscreen, Millipore) 
were coated with anti-human IFNγ monoclonal antibody 
(1-D1K; Mabtech). One day prior to plating the antigen-primed 
T cells on the ELISpot plate together with different test antigens, 
we selected cytotoxic T cells by immunomagnetic CD8 selection 
(Miltenyi Biotech). The CD8+ T cells were starved overnight in 
serum-free AIM-V medium (Gibco) and 1% glutamine (2 mM) 
to reduce ELISpot background. IFNγ secretion was detected 
using capture and detection antibodies as directed (Mabtech 
Following irradiation, the cells were incubated at 37°C until har-
vest. Two to 24 h following irradiation, K562 cells were labeled 
with AnnexinV and propidium iodide (PI) stains, according to 
the manufacturer’s instructions (BD PharMingen), and ana-
lyzed by flow cytometry (Cytomics FC 500, Beckman Coulter 
Inc.). The extent of apoptosis was defined as the percentage of 
AnnexinV positive and PI negative cells based on 50,000 events.
Isolation and preparation of monocyte-derived DCs. To 
generate DCs, frozen PBMCs were thawed and monocytes 
were selected through immunomagnetic CD14+ bead selection 
(Miltenyi Biotech). The CD14+ cells were cultured at 2 million cells 
in 3 mL of RPMI supplemented with 2% non-HI FCS (Cellgro), 
2 mM glutamine, 50 μg/mL human transferrin (Roche), 5 μg/
mL human insulin (Sigma-Aldrich), and 15 μg/mL gentamy-
cin (Invitrogen) in the presence of 120 ng/mL GM-CSF (R&D 
Systems) and 70 ng/mL IL-4 (R&D Systems) in 6-well plates. 
Additional quantities of GM-CSF (120 ng/mL) and IL-4 (70 ng/
mL) were added on days 3 and 5 to generate iDCs. DCs were 
matured on day 7 by addition of a cocktail consisting of GM-CSF 
Figure 5. skin reactions characterized by erythema, swelling and 
warmth occurred commonly at the immunization site, following sc/
id injection of irradiated GM-csF secreting K562 cells. These reactions 
were transient, lasting 1–5 d following vaccination.
Table 3. clinical characteristics of GM-csF secreting irradiated K562 
cell treated cML patient samples whose pBMc were tested by eLIspot 
against the K562 cross-presentation assay
Patient Age/Sex
Previous 
therapy
Imatinib maximum dose; 
length of treatment
a 42/M - 800 mg/daily; 2 y
B 45/M hydroxyurea 800 mg/daily; 1 y
c 55/M hydroxyurea 800 mg/daiy; 5 ywww.landesbioscience.com OncoImmunology  1101
CD4 (clone 13B8.2; Beckman-Coulter); FOXP3 (clone PCH101; 
eBioscience), and CD25 (clone B1.49.9; Beckman-Coulter).
Statistical analyses. Two-tailed Student’s t-test with pooled 
variance were applied to determine the difference between 
groups. p values < 0.05 were considered significant.
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